DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ENALAPRILAT
» See Plans and Pricing
All Clinical Trials for Enalaprilat
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00741156 | The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution | Completed | The Hospital for Sick Children | Phase 3 | 2008-07-01 | The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients. |
| NCT01324245 | Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet | Completed | University of Virginia | N/A | 2002-11-01 | The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure. |
| NCT01324245 | Intervention Study to Compare the Natriuretic Effects of Enalapril on Low and High Salt Diet | Completed | Georgetown University | N/A | 2002-11-01 | The kidney plays a crucial role in maintaining salt balance by two opposing physiological mechanisms: the renal dopaminergic system which enhances salt excretion and the renin-angiotensin system (RAS) which causes salt retention. Salt-sensitive hypertension occurs when this balance is altered or abnormal. We hypothesized that this balance is influenced by salt intake: therefore dietary salt affects the natriuretic response to the renal dopaminergic agonist Fenoldopam, and the Angiotensin Converting Enzyme inhibitor, Enalapril. In this trial we study normal salt balance mechanisms in salt resistant adults with normal blood pressure. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Enalaprilat
Condition Name
Clinical Trial Locations for Enalaprilat
Trials by Country
Clinical Trial Progress for Enalaprilat
Clinical Trial Phase
Clinical Trial Sponsors for Enalaprilat
Sponsor Name
